The in vitro activity of Cabozantinib as first- and second-line agent in metastatic renal cell carcinoma

被引：0
|
作者：
Zaccagnino, Angela [1 ]
Vynnytska-Myronovska, Bozhena [2 ]
Stoeckle, Michael [1 ]
Junker, Kerstin [1 ]
机构：
[1] Saarland Univ, Dept Urol & Pediat Urol, Homburg, Germany
[2] Univ Saarland, Homburg, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 3期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
195
引用
收藏
页码：102 / 102
页数：1
相关论文
共 50 条
  • [1] An in vitro comparison between Cabozantinib as first- and second-line agent in metastatic renal cell carcinoma
    Zaccagnino, A.
    Vynnytska-Myronovska, B.
    Stoeckle, M.
    Junker, K.
    EUROPEAN UROLOGY, 2021, 79 : S751 - S751
  • [2] Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting
    Procopio, Giuseppe
    Derosa, Lisa
    Gernone, Angela
    Morelli, Franco
    Sava, Teodoro
    Zustovich, Fable
    De Giorgi, Ugo
    Ferrari, Vittorio
    Sabbatini, Roberto
    Gasparro, Donatello
    Felici, Alessandra
    Burattini, Luciano
    Calvani, Nicola
    Lo Re, Giovanni
    Banna, Giuseppe
    Brizzi, Maria Pia
    Rizzo, Mimma
    Ciuffreda, Libero
    Iacovelli, Roberto
    Ferrau, Francesco
    Taibi, Eleonora
    Bracarda, Sergio
    Porta, Camillo
    Galligioni, Enzo
    Contu, Antonio
    FUTURE ONCOLOGY, 2014, 10 (10) : 1741 - 1750
  • [3] First and Second-line Treatments in Metastatic Renal Cell Carcinoma
    Barragan-Carrillo, Regina
    Saad, Eddy
    Saliby, Renee-Maria
    Sun, Maxine
    Albiges, Laurence
    Bex, Axel
    Heng, Daniel
    Mejean, Arnaud
    Motzer, Robert J.
    Plimack, Elizabeth R.
    Powles, Thomas
    Rini, Brian I.
    Zhang, Tian
    Choueiri, Toni K.
    EUROPEAN UROLOGY, 2025, 87 (02) : 143 - 154
  • [4] Cabozantinib as a Second-Line Agent in Advanced Hepatocellular Carcinoma
    Kudo, Masatoshi
    LIVER CANCER, 2018, 7 (02) : 123 - 133
  • [5] Progressive metastatic medullary thyroid carcinoma: first- and second-line strategies
    Links, Thera P.
    Verbeek, Hans H. G.
    Hofstra, Robert M. W.
    Plukker, John Th M.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2015, 172 (06) : R241 - R251
  • [6] Cabopoint: a phase II study of second-line cabozantinib in patients with metastatic renal cell carcinoma (RCC)
    Ivanyi, P.
    Albiges, L.
    Schmidinger, M.
    Taguieva-Pioger, N.
    Perol, D.
    Gruenwald, V
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 274 - 274
  • [7] CaboPoint: a Phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma
    Albiges, Laurence
    Schmidinger, Manuela
    Taguieva-Pioger, Naila
    Perol, David
    Grunwald, Viktor
    Guemas, Eric
    FUTURE ONCOLOGY, 2022, 18 (08) : 915 - 925
  • [8] CaboPoint: A phase II study of second-line cabozantinib in patients with metastatic renal cell carcinoma (RCC)
    Albiges, L.
    Schmidinger, M.
    Taguieva-Pioger, N.
    Perol, D.
    Gruenwald, V.
    ANNALS OF ONCOLOGY, 2020, 31 : S608 - S609
  • [9] Advanced Renal Cell Carcinoma Cabozantinib Monotherapy is the Second-line Therapy Standard
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (11) : 638 - 639
  • [10] First- and second-line therapy of metastatic colorectal cancer
    Terstriep, Shelby
    Grothey, Axel
    EXPERT REVIEW OF ANTICANCER THERAPY, 2006, 6 (06) : 921 - 930
12345